Pfizer stock offers a beefy dividend yield. This options strategy makes the drugmaker's yield even more appealing.

PFE holds above key SMAs with a 2026 rally, but weak guidance, COVID declines, and patent risks cloud its recovery outlook ...

Up until recently, the stock has been a chronic underperformer.

Pfizer is behind Eli Lilly and Novo Nordisk in the GLP-1 race, but long-term investors shouldn't count the company out.

Pfizer Inc. shares ticked up modestly Tuesday as investors weighed fresh positive oncology data against the pharmaceutical ...

Good news has been scarce for this beaten-down drugmaker.

Pfizer has quietly built momentum in 2026 and Guggenheim just raised its price target to $36 while reiterating a Buy rating.

They aren't just "pandemic stocks." ...

Pfizer (NYSE: PFE) got a huge boost during the coronavirus pandemic thanks to its COVID-19 vaccine. Since that point, however, investors have soured on the stock, which has lost more than half its ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...

Pfizer beat on 2025 sales and beat on earnings -- but still delivered a loss. Pfizer reaffirmed 2026 sales and earnings guidance for under $3 per share. 10 stocks we like better than Pfizer › Pfizer ...